non-Hodgkins Lymphoma (CD20 positive, follicular) which is refractory to rituximab and relapsed following chemotherapy.
| Source | Link | Revision Date | Access Date |
| Bexxar Prescribing Information | http://www.bexxar.com/ | 2005-October | 2008-June-02 |
| Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11):1767-76 | http://www.ncbi.nlm.nih.gov/pubmed/17942813 | 2008-May-29 | |
| Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000 Aug 15;96(4):1259-66 | http://bloodjournal.hematologylibrar...full/96/4/1259 | 2008-May-29 | |
| Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000 Mar;18(6):1316-23 | http://www.ncbi.nlm.nih.gov/pubmed/10715303 | 2008-May-29 | |
| Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001 Oct 1;19(19):3918-28 | http://www.ncbi.nlm.nih.gov/pubmed/11579112 | 2008-May-29 | |
| Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005 Feb 1;23(4):712-9 | http://www.ncbi.nlm.nih.gov/pubmed/15613695 | 2008-May-29 | |
| Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005 Feb 3;352(5):441-9 | http://content.nejm.org/cgi/content/full/352/5/441 | 2008-May-29 | |
| Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol. 2005 Jan 20;23(3):461-7 | http://www.ncbi.nlm.nih.gov/pubmed/15534357 | 2008-May-29 | |
| Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003 Apr;30(2 Suppl 4):31-8 | http://www.ncbi.nlm.nih.gov/pubmed/12728405 | 2008-May-29 | |
| Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004 Dec 1;10(23):7792-8 | http://clincancerres.aacrjournals.or...ull/10/23/7792 | 2008-May-29 | |
| Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005 Aug 20;23(24):5696-704 | http://www.ncbi.nlm.nih.gov/pubmed/16110029 | 2008-May-29 |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2008 Clinical Immunology Society | Web Site Disclaimer |
